Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Nov 15, 2026 is 274.84. In the previous year, Cash Conversion Cycle (CCC) was 372.78 — a change of -26.27% (lower).

Cash Conversion Cycle

274.84

YoY

-26.27%

Last updated:

Cash Conversion Cycle (CCC) of Laboratorios Farmaceuticos ROVI is 2025 274.84 . Cash Conversion Cycle (CCC) of Laboratorios Farmaceuticos ROVI was 2024 372.78 . It decreases by -26.27% lower compared to the previous year.

The Laboratorios Farmaceuticos ROVI Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
205.79 EUR
Jan 1, 2019
275.31 EUR
Jan 1, 2020
400.95 EUR
Jan 1, 2021
289.32 EUR
Jan 1, 2022
310.61 EUR
Jan 1, 2023
305.97 EUR
Jan 1, 2024
372.78 EUR
Jan 1, 2025
274.84 EUR
The Laboratorios Farmaceuticos ROVI Cash Conversion Cycle history
YEARCash Conversion CycleYoY
274.84-26.27%
372.78+21.83%
305.97-1.49%
310.61+7.36%
289.32-27.84%
400.95+45.63%
275.31+33.78%
205.79+15.30%
178.49+51.03%
118.18-29.81%
168.39+4.45%
161.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Cash Conversion Cycle (CCC) of Laboratorios Farmaceuticos ROVI is 274.84 in 2025.

Cash Conversion Cycle (CCC) of Laboratorios Farmaceuticos ROVI changed from 372.78 to 274.84, representing a -26.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Laboratorios Farmaceuticos ROVI with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI